DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
“Can Ozempic make you go blind?” is the search. The real answer is narrower and less terrifying than the headlines: a rare optic-nerve condition called NAION, a small absolute risk in the studies that found any link at all, and conflicting evidence overall. Here is what is actually known, in numbers.
NAION — non-arteritic anterior ischemic optic neuropathy — is what happens when blood flow to the front of the optic nerve is suddenly reduced, damaging the nerve. People typically wake up with painless loss or blurring of vision in one eye, often a missing region of the visual field. It is uncommon in the general population, and when it happens the vision loss is frequently permanent. This — not general “blindness” — is the specific event behind the Ozempic headlines.
The signal started with a 2024 JAMA Ophthalmology studyfrom Harvard’s Mass Eye and Ear, which found people with diabetes on semaglutide had a higher rate of NAION. Larger datasets followed: a Danish cohort of 424,152 people with type 2 diabetes found once-weekly semaglutide more than doubled the five-year risk. But “doubled” is a relative number, and the base rate is low. In absolute terms, pooled incidence was roughly 2.3–2.7 cases per 10,000 patient-years on semaglutide versus about 1.9 per 10,000 without it — which UK regulators translated as about one additional affected person for every 10,000 people treated per year. In several studies the increase only showed up after about two years of use.
The evidence is genuinely inconsistent. Some cohort and pharmacovigilance studies support the link; others found no significant increase. All of them are observational, so they can show association but not causation — and the people taking these drugs already have diabetes and obesity, which independently raise vascular risk. The joint NANOS and American Academy of Ophthalmology consensus is that a possible association exists but is not established, and that it does not, on its own, justify stopping a medication someone needs. The UK MHRA reviewed the same evidence in a February 2026 drug-safety update and advised awareness rather than discontinuation.
NAION has well-known risk factors, and they matter more than the drug question for most people: a “disc at risk” (a small, crowded optic disc — usually discovered only on an eye exam), a prior NAION in the other eye, and vascular risk factors like high blood pressure and sleep apnea. If you have already had NAION in one eye, that is the single strongest reason to discuss this with both your prescriber and an ophthalmologist before starting or continuing a GLP-1. For most people without those factors, the small absolute risk sits alongside the drug’s substantial cardiometabolic benefits.
Forget trying to weigh hazard ratios in the moment. The rule is simple: sudden, painless loss or blurring of vision in one eye — a dark spot, a curtain, a missing area — is a same-day emergency, whatever the cause. Seek urgent eye care or emergency care; do not wait to see if it clears. That single behavior matters far more than the statistical debate, because early assessment is what protects vision.
Weighing the whole safety picture? See the full GLP-1 side effects by drug and symptom and our Ozempic review.